Speaker: Alex Rampotas

0:01:05

Novel CAR-Ts to improve poor outcomes for patients with relapsed T-ALL post-transplant

0:01:07

The real-world efficacy of CAR-T cells in post-transplant relapsed B-ALL

0:01:06

How will novel agents & CAR-T cells affect the future treatment landscape in B-ALL?

0:01:43

Personalizing treatment for MPNs by selecting between JAK inhibitors

0:02:05

Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting

0:01:38

The future of CAR-T for hematological malignancies and solid tumors

0:04:34

Development and evaluation of a novel CAR-T cell therapy against CALR mutant neoplasms

0:02:37

Real-world efficacy and safety of momelotinib for myelofibrosis: evaluation of a UK-wide study

0:00:44

The recent FDA approval of ponatinib for Ph+ ALL following success in the PhALLCON trial

0:01:15

Comparing the efficacy of salvage therapies in adult B-ALL: a retrospective real-world study

0:08:03

Development and evaluation of a first-in-class CAR-T therapy against calreticulin-mutant neoplasms